Medicus Pharma Celebrates Nasdaq Listing Anniversary with Phase 2 Advances
ByAinvest
Saturday, Jan 24, 2026 4:34 am ET1min read
MDCX--
Medicus Pharma marks its one-year anniversary on Nasdaq by ringing the opening bell at the Nasdaq MarketSite in New York. The company is advancing two Phase 2 clinical programs, SkinJect for basal cell carcinoma and Teverelix for advanced prostate cancer. Medicus estimates the combined market opportunity for its pipeline assets at approximately $6 billion. The royalty rate payable on Teverelix has been reduced from 4% to 2%, improving its profile for future partnering.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet